SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/22/24 Annovis Bio, Inc. 8-K:8 3/22/24 10:188K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 26K 5: R1 Cover HTML 49K 7: XML IDEA XML File -- Filing Summary XML 11K 10: XML XBRL Instance -- tm249453d2_8k_htm XML 16K 6: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 3: EX-101.LAB XBRL Labels -- anvs-20240322_lab XML 96K 4: EX-101.PRE XBRL Presentations -- anvs-20240322_pre XML 63K 2: EX-101.SCH XBRL Schema -- anvs-20240322 XSD 12K 8: JSON XBRL Instance as JSON Data -- MetaLinks 25± 34K 9: ZIP XBRL Zipped Folder -- 0001104659-24-037958-xbrl Zip 15K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): i March 22, 2024
(Exact Name of Registrant as Specified in Charter)
i Delaware | i 001-39202 | i 26-2540421 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
i 101
Lindenwood Drive, i Suite 225
i Malvern, i PA
i 19355
(Address of Principal Executive Offices, and Zip Code)
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
i Common Stock, par value $0.0001 per share | i ANVS | i New York Stock Exchange |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
i ¨ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
i ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
i ¨ | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
i ¨ | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i x
Item 8.01 | Other Information. |
As disclosed on the Form 8-K filed with the Securities and Exchange Commission (the “Commission”) on March 21, 2024, Annovis Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated March 21, 2024 (the “Purchase Agreement”) with an institutional investor (the “Buyer”), pursuant to which the Company agreed to issue and sell to the Buyer an aggregate of 316,455 shares of Common Stock, 0.0001 par value per share (the “Common Shares”) at $9.48 per share (the “Offering”).
On March 22, 2024, the Company closed the Offering and raised $3,000,000 in gross proceeds from the Offering. The Common Shares were issued pursuant to a currently effective shelf registration statement on Form S-3 (Registration No. 333-276814), which was filed with the United States Securities and Exchange Commission on February 1, 2024, as amended on February 12, 2024 and was declared effective on February 12, 2024.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ANNOVIS BIO, INC. | ||
Date: March 22, 2024 | By: | |
Name: Maria Maccecchini | ||
Title: President and Chief Executive Officer |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on / For Period end: | 3/22/24 | 424B5 | ||
3/21/24 | 424B5, 8-K | |||
2/12/24 | EFFECT, S-3/A | |||
2/1/24 | S-3 | |||
List all Filings |